---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000099"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:31:14.800561+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa receives FDA Fast Track for SerpinPC in hemophilia B

## Summary
- FDA granted Fast Track designation to SerpinPC, an investigational inhibitor of activated protein C.
- SerpinPC is being developed for hemophilia B, with or without inhibitors.
- Fast Track may enable expedited development and rolling review; CEO cites potential first-in-class subcutaneous therapy.
- Centessa continues to advance PRESent registrational studies for SerpinPC.

## SEC filing metadata
- accession: 0001847903-23-000099
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000099/0001847903-23-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000099/cnta-20230522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000099
- JSON: https://secwatch.observer/filing/0001847903-23-000099.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.